Author

Federica Sella

University Hospital ZurichORCID 0000-0002-0805-0905Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1 Assay:Ribo-seq· 1

Frequent Co-Authors

Mitchell Paul LevesqueiD· 2 shared Adrian BarrenoiD· 1 shared Ameya KhandekariD· 1 shared Andrea Garcia-Perez· 1 shared Angel Delgado-Lopez· 1 shared Anna MaciàiD· 1 shared Ataman SendoeliD· 1 shared Christopher Rios· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenomics

Mitchell Paul LevesqueORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

GenomicsMolecular CellPeer-reviewedMay 22, 2026

In vivo single-cell ribosome profiling reveals cell-type-specific translational programs during aging

Clara Duré, Umesh Ghoshdastider, Ramona Weber…·Ataman Sendoel

The paper uses in vivo single-cell ribosome profiling to study translational changes in mouse epidermal stem cells during aging, finding cell-type-specific translational reprogramming in aged stem cells.

3 citations

mouseRibo-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 3, 2025

Early overactivation of non-muscle myosin II during adaptation to combined BRAF and MEK inhibitors in dedifferentiating cutaneous melanomas

Andrea Garcia-Perez, Lucía Sanchez-Garcia, Marta Duran-Renieblas…·José Luis Orgaz

This study shows that non-muscle myosin II overactivation occurs in dedifferentiating melanomas adapting to BRAF and MEK inhibitors, and targeting NMII with BMi reduces drug-tolerant persister cell survival.

DOI 10.64898/2025.12.03.686756

humanproteomics

𝕏 PostBluesky